Compare FFAIW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FFAIW | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 249 | 30 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2020 | N/A |
| Metric | FFAIW | SCLXW |
|---|---|---|
| Price | $0.03 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 4.0K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | N/A | $0.18 |
| 52 Week High | N/A | $0.18 |
| Indicator | FFAIW | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 35.78 |
| Support Level | $0.03 | $0.07 |
| Resistance Level | $0.04 | $0.19 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 29.89 | 31.85 |
Faraday Future Intelligent Electric Inc is a shared intelligent mobility ecosystem. The company is poised to break the boundaries between the Internet, IT, creative, and auto industries with product and service offerings that integrate new energy, AI, Internet, and sharing models. The company has additional engineering, sales, and operational capabilities in China and plans to develop its manufacturing capability in China through a joint venture.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.